Trial Profile
Pharmacodynamic evaluation of YKP3089 in epilepsy patients with a photo-induced paroxysmal EEG [electroencephalography]-response: proof of principle.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jul 2019
Price :
$35
*
At a glance
- Drugs Cenobamate (Primary)
- Indications Epilepsy
- Focus Proof of concept; Therapeutic Use
- Sponsors SK Life Science
- 10 Jul 2019 Results assessing the effect of cenobamate on the IPS-induced EEG PPR in patients with photosensitive epilepsy published in the Neurology
- 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology
- 12 Jun 2012 Actual patient number is 11 as reported by ClincialTrials.gov.